Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,751 questions in 147 reviews · Pain, Palliative and Supportive Care
current versionsNo studies 361 · 20.6%Ungraded 87 · 5%Very low 625 · 35.7%Low 367 · 21%Moderate 232 · 13.2%High 79 · 4.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Headache relief at 15 mins · adults with cluster headache Triptans for acute cluster headache (2013) · Cochrane | RR 2.2 [0.99, 4.67] | NR | Very low |
Intervention NR At least one AE · adults with cluster headache Triptans for acute cluster headache (2013) · Cochrane | RR 1.8 [1.2, 2.8] | NR | Very low |
Intervention NR Serious AE · adults with cluster headache Triptans for acute cluster headache (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain‐free at 30 mins · adults with cluster headache Triptans for acute cluster headache (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain‐free at 15 mins · adults with cluster headache Triptans for acute cluster headache (2013) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Headache relief at 30 mins · adults with cluster headache Triptans for acute cluster headache (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain‐free at 2 h · adults with migraine headache ‐ moderate or severe pain Diclofenac with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | 2 studies · 1447 participants | Moderate |
Intervention NR Headache relief at 2 h · adults with migraine headache ‐ moderate or severe pain Diclofenac with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | 2 studies · 1447 participants | Moderate |
Intervention NR Sustained pain‐free at 24 h · adults with migraine headache ‐ moderate or severe pain Diclofenac with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | 2 studies · 1578 participants | Moderate |
Intervention NR Sustained headache relief at 24 h · adults with migraine headache ‐ moderate or severe pain Diclofenac with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR At least one AE · adults with migraine headache ‐ moderate or severe pain Diclofenac with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | 3 studies · 1075 participants | Low |
Intervention NR Serious AE · adults with migraine headache ‐ moderate or severe pain Diclofenac with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Naproxen 500 mg or 825 mg vs placebo Pain‐free response at 2 h · migraine headache ‐ moderate or severe pain Naproxen with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | NR | Moderate |
Naproxen 500 mg or 825 mg vs placebo Headache relief at 2 h · migraine headache ‐ moderate or severe pain Naproxen with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | NR | Moderate |
Naproxen 500 mg or 825 mg vs placebo Sustained pain‐free during the 24 h post dose · migraine headache ‐ moderate or severe pain Naproxen with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | NR | Moderate |
Naproxen 500 mg or 825 mg vs placebo Sustained headache relief during the 24 h post dose · migraine headache ‐ moderate or severe pain Naproxen with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | NR | Moderate |
Naproxen 500 mg or 825 mg vs placebo At least one AE · migraine headache ‐ moderate or severe pain Naproxen with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | NR | Low |
Naproxen 500 mg or 825 mg vs placebo Serious AE · migraine headache ‐ moderate or severe pain Naproxen with or without an antiemetic for acute migraine headaches in adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain end of treatment (0‐10 scale) Higher scores indicate higher pain levels · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 20 studies · 1382 participants | Low |
Cognitive behavioural therapies vs controls Health‐related quality of life end of treatment (0‐80 scale) Higher scores indicate lower health‐related quality of life · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 13 studies · 1238 participants | Low |
Cognitive behavioural therapies vs controls Fatigue · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 6 studies · 429 participants | Low |
Cognitive behavioural therapies vs controls Sleep problems · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 7 studies · 378 participants | Low |
Cognitive behavioural therapies vs controls Health‐related quality of life · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 6 studies · 425 participants | Low |
Cognitive behavioural therapies vs controls Acceptability · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 14 studies · 822 participants | Low |
Intervention NR Negative mood end of treatment (0‐10 scale) Higher scores indicate higher negative mood levels · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 18 studies · 1578 participants | Low |
Intervention NR Negative mood · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 11 studies · 721 participants | Low |
Intervention NR Disability end of treatment (0‐10 scale) Higher scores indicate disability levels · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 15 studies · 1163 participants | Low |
Intervention NR Disability · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 9 studies · 664 participants | Low |
Intervention NR Acceptability end of treatment (dropouts from study due to any reasons) · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | RR 0.94 [0.65, 1.35] | 21 studies · 1914 participants | Low |
Cognitive behavioural therapies vs controls Fatigue end of treatment (0‐10 scale) Higher scores indicate higher fatigue levels · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 11 studies · 910 participants | Low |
Cognitive behavioural therapies vs controls Sleep problems end of treatment (0‐50 scale) Higher scores indicate more sleep problems · Patients with fibromyalgia Cognitive behavioural therapies for fibromyalgia (2013) · Cochrane | no estimate extracted | 8 studies · 422 participants | Low |
Pregabalin vs placebo at end of treatment 50% pain reduction · People with fibromyalgia Anticonvulsants for fibromyalgia (2013) · Cochrane | RR 1.59 [1.33, 1.9] | 5 studies · 3256 participants | High |
Pregabalin vs placebo at end of treatment Patient Global Impression of Change of 'much' or 'very much' improved · People with fibromyalgia Anticonvulsants for fibromyalgia (2013) · Cochrane | RR 1.38 [1.23, 1.55] | 5 studies · 3183 participants | High |
Pregabalin vs placebo at end of treatment Fatigue (1‐50 scale) Higher scores indicate higher fatigue levels · People with fibromyalgia Anticonvulsants for fibromyalgia (2013) · Cochrane | no estimate extracted | 5 studies · 3195 participants | High |
Pregabalin vs placebo at end of treatment Sleep problems (0‐100 scale). Higher scores indicate more sleep problems · People with fibromyalgia Anticonvulsants for fibromyalgia (2013) · Cochrane | no estimate extracted | 5 studies · 3139 participants | High |
Pregabalin vs placebo at end of treatment Withdrawal due to adverse events · People with fibromyalgia Anticonvulsants for fibromyalgia (2013) · Cochrane | RR 1.68 [1.36, 2.07] | 5 studies · 3259 participants | High |
Pregabalin vs placebo at end of treatment Serious adverse events · People with fibromyalgia Anticonvulsants for fibromyalgia (2013) · Cochrane | RR 1.03 [0.71, 1.49] | 4 studies · 2729 participants | Moderate |
Pregabalin vs placebo at end of treatment Dizziness reported to be an adverse event · People with fibromyalgia Anticonvulsants for fibromyalgia (2013) · Cochrane | RR 3.77 [3.06, 4.63] | 5 studies · 3257 participants | High |
Radioisotopes vs Placebo Pain relief ‐ Complete relief · patients with metastatic bone pain Radioisotopes for metastatic bone pain (2011) · Cochrane | RR 2.1 [1.32, 3.35] | 4 studies · 296 participants | Moderate |
Radioisotopes vs Placebo Pain relief ‐ Complete/Partial relief · patients with metastatic bone pain Radioisotopes for metastatic bone pain (2011) · Cochrane | RR 1.72 [1.13, 2.63] | 3 studies · 119 participants | Moderate |
Radioisotopes vs Placebo Compression of spinal cord · patients with metastatic bone pain Radioisotopes for metastatic bone pain (2011) · Cochrane | RR 1.1 [0.39, 3.07] | 2 studies · 270 participants | Low |
Radioisotopes vs Placebo Pain flares · patients with metastatic bone pain Radioisotopes for metastatic bone pain (2011) · Cochrane | RR 0.74 [0.27, 2.06] | 2 studies · 270 participants | Low |
Radioisotopes vs Placebo Thrombocytopenia III‐IV · patients with metastatic bone pain Radioisotopes for metastatic bone pain (2011) · Cochrane | RR 2.21 [0.98, 4.99] | 4 studies · 313 participants | Low |
Radioisotopes vs Placebo Leucocytopenia III‐IV · patients with metastatic bone pain Radioisotopes for metastatic bone pain (2011) · Cochrane | RR 5.9 [1.62, 21.47] | 4 studies · 410 participants | Low |
Methylnaltrexone vs placebo Rescue free laxation within 4 hours · patients with the management of opioid‐induced constipation in palliative care patients Laxatives or methylnaltrexone for the management of constipation in palliative care patients (2011) · Cochrane | OR 6.95 [3.83, 12.61] | 2 studies · 287 participants | Moderate |
Methylnaltrexone vs placebo Rescue free laxation within 24 hours · patients with the management of opioid‐induced constipation in palliative care patients Laxatives or methylnaltrexone for the management of constipation in palliative care patients (2011) · Cochrane | OR 5.42 [3.12, 9.41] | 2 studies · 287 participants | Moderate |
Psychostimulants vs placebo Fatigue score change Drug therapy for the management of cancer‐related fatigue (2010) · Cochrane | no estimate extracted | 5 studies · 410 participants | High |
Intervention NR Complete pain relief · Patients withmetastatic bone pain Calcitonin for metastatic bone pain (2006) · Cochrane | RR 2.5 [0.55, 11.41] | 1 study · 40 participants | Very low |
Intervention NR Less or equal analgesia consumption · Patients withmetastatic bone pain Calcitonin for metastatic bone pain (2006) · Cochrane | RR 1.05 [0.9, 1.21] | 1 study · 48 participants | Very low |